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INTRODUCTION:  Merkel  Cell  Carcinoma  is an  aggressively  malignant,  neuroendocrine-derived,  cutaneous
neoplasm  that  commonly  affects  sun-exposed  areas  of  the  elderly  population.  MCC  typically  presents  as
a rapidly  enlarging,  painless  nodule  that  is red  to purple  in color  and located  on  sun exposed  areas  such
as  the  head,  neck  and  arms.  Although  rare, cases  of  MCC  on non-sun  exposed  skin  have  been  documented
and  typically  have  a worse  prognosis.
PRESENTATION  OF  CASE:  We  report  an atypical  case  of  Merkel  Cell  Carcinoma  originating  in a  non-
sun  exposed  area  of  the  body  with  evidence  of distant  metastasis.  A  76-year-old  male  presented  with
complaints  of a ﬁrm  lesion  in his  left  gluteal  fold.
DISCUSSION:  Clinical  diagnosis  of  MCC  is usually  made  from  a combination  of  history  and physical,
skin  and  nodal  examination,  biopsy  sample  with  H&E prep,  and  immunopanel.  Treatment  according
to  the  National  Comprehensive  Cancer  Network® (NCCN®) is directed  by  lymph  node  involvement  and
metastasis.
CONCLUSION:  With  initial  unsuccessful  treatment,  his lesion  was  excised  and  pathological  evaluation
reported  Merkel  Cell  Carcinoma  (MCC).  Despite  further  surgical  excision  and  adjuvant  chemotherapy,
increased  hyper  metabolism  was  found  in the left  descending  colon  and  left prostate  of  unknown  etiology.
There  have  been  reports  of  metastasis  of primary  MCC  to the  small  bowel  mesentery;  therefore  new  focal
hyper  metabolism  cannot  be  delineated  precisely  as  unrelated  to  MCC  until biopsy  and  histochemical
staining  are  performed.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Merkel Cell Carcinoma (MCC) is an aggressively malignant,
euroendocrine-derived, cutaneous neoplasm that commonly
ffects sun-exposed areas of the elderly population [1]. The etiol-
gy is likely multifactorial with immunosuppression, UV-induced
kin damage, and viral factors, such as Merkel Cell Polyomavirus
MCPyV) contributing to the development of this neoplasm [1,2].
ccurrence of MCC  is rare, but it does have the fastest increas-
ng incidence of all skin cancers showing a 0.15–0.44 per 100,000
ncrease from 1986 to 2001 [3]. MCC  typically presents as a rapidly
nlarging, painless nodule that is red to purple in color and located
n sun exposed areas such as the head, neck and arms [4]. Although
are, cases of MCC  on non-sun exposed skin have been documented
nd typically have a worse prognosis [5]. The risk for developing
CC is increased in the elderly and male populations, as well as in
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those with high UV exposure or who are immunosuppressed [4].
This malignancy almost exclusively affects Caucasian populations,
with 98% of all cases occurring in this demographic, suggesting pos-
sible protection by darker skin pigmentation [6]. Early locoregional
metastasis is typical of MCC  and is associated with 5 year survival
rate of 50% [7]. Once MCC  has undergone distant metastasis the
1 year survival rate drops to 44% [7].
2. Presentation of case
2.1. Initial presentation
A 76 year old, Caucasian male presented to his primary care
physician one-month post-op from an orthopedic back procedure
with a chief complaint of a sore in the inner crease of his left glu-
teus. The patient stated that the sore had remained the same size
over the previous month, and it was  noted on physical exam to
be a ﬁrm, red nodule that was  not warm to the touch. The lesion
was also moveable and elicited a stinging sensation on palpation.
An initial diagnosis of cellulitis with abscess was made and the
patient was started on a ten-day course of TMP-Sulfamethoxazole.
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Excisional biopsy of the lesion located in the left gluteal crease revealed Merkel Cell Carcinoma with positive margins (02/11/2015).
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pig. 2. Images of the PET scan one month post-surgical excision showing largest mas
4.13.15).
t a follow-up appointment one week later it was revealed that
he lesion no longer stung, but that the patient was still distressed
y its presence. The patient was then referred to a plastic surgeon
ith a suspected diagnosis of cellulitis and abscess with associ-
ted fat necrosis. Surgical excision of the lesion was  completed
ne month after the patient’s initial visit. Pathological evaluation
f the specimen following excision revealed a diagnosis of Merkel
ell carcinoma with positive margins (Fig. 1).
.2. Treatment courseA second surgical procedure took place two weeks later in order
o obtain negative margins conﬁrmed by frozen section. A PET scan
erformed one month later revealed several subcutaneous massesasuring 2.3 × 1.8 cm and 2 × 2 cm with SUV max  values of 13.3 and 10.4 respectively
involving the left buttock extending to the midline (Fig. 2). Addi-
tionally, a 2.1 cm left external iliac inguinal node showed a SUV max
of 15.7. Three weeks following the PET scan, the patient underwent
a radical resection of his bilateral buttocks in addition to a sentinel
node procedure. Negative margins were achieved and two positive
nodes were removed. A second PET scan performed two months
later revealed a nodule in the right lung in addition to a nodular
focus in the subcutaneous adipose tissue of the left gluteal region
(Fig. 3). This scan also showed a right inguinal node.2.3. Adjuvant therapy
Two weeks later the patient began a two-month course of
chemotherapy consisting of Cisplatin and Etoposide. Two  weeks
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Fig. 3. A second PET scan performed after the third radical resection revealing a 1.7 × 0.6 cm nodule with a SUV max  of 3.12 in the right lung in addition to a 9 mm nodular
focus  in the subcutaneous adipose tissue of the left gluteal region with a SUV max  of 3.5. A right inguinal node was also present measuring 2.6 × 1.8 cm with a SUV  max  of
13.29  (7.08.15).
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tig. 4. Third PET scan showing resolution of the right middle lobe lung nodule as 
ax  of 1.59. The left gluteal hyperdensity in the subcutaneous adipose tissue measu
can.  Increased metabolism is noted in the descending colon and left lateral prostatollowing completion of the patient’s chemotherapy, a third PET
can was performed. The scan revealed interval resolution of both
he previously identiﬁed lung nodule as well as the right inguinals interval resolution of the right inguinal node measuring 1.7 × 0.8 cm with a SUV
 SUV max  of 2.0, but this is decreased from its SUV max value of 5.27 on a previous
05.15).node. The left gluteal region showed some hyper density in the sub-
cutaneous adipose tissue, but shows a reduction in comparison to
the previous scan. The scan also revealed increase splenic uptake,
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hich was thought to be the result of chemotherapy. Incidental
ndings of focal hyper metabolism in the descending colon and left
ateral aspect of the prostate were also noted (Fig. 4).
. Discussion
.1. Diagnosis
Clinical diagnosis of MCC  is usually made from a combina-
ion of history and physical, skin and nodal examination, biopsy
ample with H&E prep, and immunopanel [8]. Due to the non-
peciﬁc, benign clinical appearance of the initial lesion, MCC  is
eldom suspected prior to biopsy [9]. An appropriate immunopanel
hould include CK20 and thyroid transcription factor-1 (TTF-1) [8].
mmunohistochemistry for CK20 and most low-molecular-weight
ytokeratin markers (pancytokeratins AE1/AE3) are typically posi-
ive [8].
After diagnosis of MCC, clinical workup involves imaging studies
o identify and quantify regional and distant metastasis. PET-CT
s the preferred imaging technique according to some studies. If
ET-CT is unavailable, CT or MRI  may  be used [8].
.2. Treatment
Treatment according to the National Comprehensive Cancer
etwork® (NCCN®) is directed by lymph node involvement and
etastasis [8]:
Clinical N0 — Management of the primary tumor is wide local
xcision with adjuvant radiation therapy to the primary tumor site.
entinel lymph node biopsy evaluation with immunopanel is per-
ormed for management of the draining nodal basin.
Clinical N+ — Fine needle aspiration (FNA) or core biopsy is per-
ormed with immunopanel. Imaging studies or open biopsy are
onsidered when the FNA is positive or negative respectively. Node
issection and radiation therapy is performed for positive nodal
nvolvement without distant metastasis. Follow up visits should
nclude complete skin and lymph node exam every 3–6 months for
 years, then every 6–12 months thereafter for recurrence.
Clinical M1  — A combination of excision, regional radiation ther-
py and chemotherapy is considered. Cisplatin and Etoposide are
sed in combination. Clinical trials are preferred if available.
.3. Clinical trials
Numerous trials are underway in search of advancement in
herapy. Pembrolizumab, a programmed death receptor antago-
ist used to combat other forms of cancer, is currently undergoing
 clinical trials [10]. The death receptor is a molecule expressed
y lymphocytes that when bound by its ligand can suppress the
mmune system’s ability to combat cancer [11]. By blocking the
eceptor-ligand interaction, Pembrolizumab is aimed at decreasing
mmune-suppression and thus increasing the body’s ability to fend
ff neoplastic cells. Additionally there are trials using Cabozantinib,
hich is a MET/VEGFR2 inhibitor [12]. MET/VEGFR2 are molecules
nvolved in angiogenesis and cell survival/motility, which all play
 key role in the progression of neoplasia [12]. Finally, it has been
ypothesized that infusion of autologous CD8-positive T cells that
re primed for MCPyV Ag along with concurrent IL-2 therapy may
e a new mechanism to target therapy against Merkel cell carci-
oma [13]. The Merkel cell polyomavirus (MCPyV) is theorized to
ntegrating in to the host cell’s genome leading to clonal expansion,
ll the while preventing viral replication via a mutation to ensure
ost cell survival [14,15].PEN  ACCESS
ery Case Reports 23 (2016) 177–181
4. Conclusion
This patient presented with a unique case of Merkel cell carci-
noma. Although he is elderly, the location of the lesion and the fact
that he is immunocompetent with no comorbid illness, suggests an
atypical presentation of MCC. It is not clear whether his incidental
ﬁndings of focal hyper metabolism in the descending colon and left
prostate are related to MCC  at this time. There have been reports
of metastasis of primary MCC  to the small bowel mesentery, there-
fore new focal hyper metabolism cannot be delineated precisely
as unrelated to MCC  until biopsy and histochemical staining are
performed [9].
Surgical debridement was  performed initially, but adjuvant
radiotherapy was delayed due to the initial uncertainty of the
diagnosis. Due to systemic metastasis of MCC, chemotherapy was
initiated prior to radiation therapy once the diagnosis was made.
After 2 months in remission this cancer relapsed, consistent with
its aggressively malignant nature. We  will continue to follow pend-
ing further investigation of the descending colon. It is our hope that
with increased knowledge and awareness of atypical presentations
of Merkel cell carcinoma, we can detect and address this disease in
its infancy prior to any metastasis and spare future patients the
same clinical course.
Update: Since relapse, the patient’s condition deteriorated. 14
months since diagnosis, the patient has passed away from compli-
cations of Merkel Cell Carcinoma.
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